Physician profile
Reshma C Vora
NPI 1962605816
$3,806.90
in general payments reported to CMS, 2019-2025
40 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $23.52 · 2021: $35.28 · 2022: $568 · 2023: $1,098 · 2024: $1,063 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $771.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $700.00 | 2019-2025 | Ubrelvy, Qulipta, Skyrizi |
| Glaxosmithkline, LLC. | $237.53 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Abbott Laboratories | $232.60 | 2022-2024 | Eterna, Freestyle Libre 3 |
| Lilly USA, LLC | $212.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $210.16 | 2019-2024 | |
| Pfizer INC. | $164.17 | 2022-2025 | |
| Amgen INC. | $121.98 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $94.87 | 2019-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.10 | 2019-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $84.01 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.56 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $72.75 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $46.16 | 2022 | |
| Astellas Pharma US INC | $45.08 | 2023-2024 | Veozah |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.